Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 26, 2007

Goodwin Biotechnology to Produce Neogenix’ mAb for Pancreatic Cancer

  • Neogenix Oncology and Goodwin Biotechnology entered into an agreement for process development and manufacturing of Neogenix’ first therapeutic product. NPC-1C is a mAb intended for the treatment of advanced pancreatic cancer.

    Neogenix expects to begin Phase I and Phase II trials of the product during the first half of 2008.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »